Search
Close this search box.

FDA Backs Pfizer COVID-19 Boosters for Seniors, High-risk

FDA Backs Pfizer COVID-19 Boosters for Seniors, High-risk

Washington, The United States (US) moved a step closer to offering booster doses of Pfizer’s COVID-19 vaccine to senior citizens and others at high risk from the virus as the Food and Drug Administration (FDA) signed off on the targeted use of extra shots.

The FDA authorized booster doses for Americans who are 65 and older, younger adults with underlying health conditions and those in jobs that put them at high risk for COVID-19. The ruling represents a drastically scaled back version of the Biden administration’s sweeping plan to give third doses to nearly all American adults to shore up their protection amid the spread of the highly contagious delta variant.

However, more regulatory hurdles lie ahead before the dispensing of boosters can begin.

The FDA decision was expected after the agency’s own panel of advisers last week overwhelmingly rejected the Biden plan. The panel instead recommended boosters only for those most vulnerable to severe cases of COVID-19, the Associated Press (AP) reported.

Source: Oman News Agency